
Darolutamide with ADT and radiation cuts metastasis or death risk by 58% in high-risk prostate cancer patients.
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...





